Abstract
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum- based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.
MeSH terms
-
Aged
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / complications
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Erlotinib Hydrochloride
-
Female
-
Humans
-
Intestinal Fistula / chemically induced*
-
Intestinal Fistula / complications
-
Intestinal Fistula / diagnostic imaging
-
Intestinal Fistula / surgery
-
Intestinal Perforation / chemically induced*
-
Intestinal Perforation / complications
-
Intestinal Perforation / diagnostic imaging
-
Intestinal Perforation / surgery
-
Protein Kinase Inhibitors / adverse effects*
-
Protein Kinase Inhibitors / therapeutic use
-
Quinazolines / adverse effects*
-
Quinazolines / therapeutic use
-
Radiography
-
Sigmoid Diseases / chemically induced*
-
Sigmoid Diseases / complications
-
Sigmoid Diseases / diagnostic imaging
-
Sigmoid Diseases / surgery
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Quinazolines
-
Erlotinib Hydrochloride